Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
14 angezeigte Treffer · Seite 3, keine Gesamtzahl für „upadacitinib“
Suchtreffer
Begriffe & Kennungen
Rinvoq · 4.8 · The long-term rate of herpes zoster through week 260 for the upadacitinib 15 mg and 30 mg groups was 3.2 and 5
Eintrag öffnenRinvoq · 4.8 · The long-term rate of herpes zoster through week 260 for the upadacitinib 15 mg and 30 mg groups was 3.2 and 5
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib 15 mg and 30 mg observed in patients with alopecia areata was generally con
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib 15 mg and 30 mg observed in patients with alopecia areata was generally con
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib 15 mg observed in patients with vitiligo was generally consistent with the
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib 15 mg observed in patients with vitiligo was generally consistent with the
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib with long-term treatment was generally similar to the safety profile during
Eintrag öffnenRinvoq · 4.8 · The safety profile of upadacitinib with long-term treatment was generally similar to the safety profile during
Eintrag öffnenRinvoq · 4.8 · Upadacitinib 15 mg treatment was associated with increases in lipid parameters including total cholesterol, tr
Eintrag öffnenRinvoq · 4.8 · Upadacitinib 15 mg treatment was associated with increases in lipid parameters including total cholesterol, tr
Eintrag öffnenRinvoq · 4.8 · • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 62% vs. 31%, in the upadacitinib 15 mg and placebo groups, resp
Eintrag öffnenRinvoq · 4.8 · • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 62% vs. 31%, in the upadacitinib 15 mg and placebo groups, resp
Eintrag öffnenupadacitinib
Eintrag öffnenupadacitinib
Eintrag öffnen